PHILADELPHIA, Pennsylvania — A combination of dextromethorphan and quinidine (Nuedexta, Avanir Pharmaceuticals) significantly reduced symptoms of pseudobulbar affect (PBA) among patients with dementia ...
FDA grants Priority Review to AXS-05 (dextromethorphan/bupropion) for the treatment of agitation associated with Alzheimer disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results